Mankind Pharma's Rs 10,000 crore debt bet on Bharat Serums: Masterstroke or risky gamble?

Mankind Pharma, India's fourth-largest pharmaceutical company, is going all in on its latest acquisition. Historically known for its debt-free status, the pharma giant is going to raise Rs 10,000 crore through non-convertible debentures and commercial paper to fund its Rs 13,630 crore acquisition of Bharat Serums & Vaccines (BSV). In addition, it may dilute equity and raise another Rs 3,000 crore through a Qualified Institutional Placement (QIP).

With the total funds being raised greater than the existing balance sheet size, the stakes are not just high—they are unprecedented. So, is the risk worth it? To determine that, we must consider three key questions that serve as a litmus test for any acquisition.

Q1: Does the acquisition provide new growth opportunities?

The answer appears to be yes. BSV specialises in women's health, particularly in fertility, pregnancy, and post-pregnancy care. As fertility rates decline, demand for BSV's fertility products has been on the rise. Furthermore, fewer than 1 per cent of the 28 million Indian couples attempting to conceive have opted for IVF (In Vitro Fertilisation), pointing to a significant untapped market. Thus, BSV's product offerings could become a major growth lever in Mankind Pharma's portfolio, helping the company capitalise on this growing demand.

Q2: Does the acquisition align with the company's long-term strategic goals?

Yes. Mankind Pharma is well-known for its diverse consumer health portfolio, which includes fertility and gynaecological products. BSV's women's health offerings will complement Mankind's existing product line and strengthen its leadership position in the gynaecology segment. Notably, Mankind Pharma would become India's leading pharmaceutical company in the gynaecology segment following the acquisition. Additionally, Mankind's vast distribution network could significantly expand the reach of BSV's products.

Q3: Is the price right?

This is a more nuanced question. Mankind Pharma is set to acquire BSV for an enterprise value of Rs 13,630 crore. BSV reported sales of Rs 1,723 crore and an EBITDA of Rs 489 crore in FY24. This puts BSV's EV/Sales multiple at 8x and its EV/EBITDA multiple at 28x—higher than the industry average for similar pharmaceutical companies.

However, BSV enjoys impressive profitability, with an EBITDA margin of 28 per cent and market-leading positions for several of its key brands. Its net margin is also stronger than Mankind Pharma's, which may justify the premium paid. While the boost in earnings from BSV may not immediately offset the rise in interest expenses resulting from the debt raise, Mankind's robust cash generation ability should mitigate this concern. The company generated Rs 1,728 crore in free cash flow in FY24 and currently holds a cash balance of Rs 3,000 crore, giving it some financial cushion.

Final verdict

While the scale of the fund raise is undoubtedly a bold move, the potential rewards of this acquisition seem to outweigh the risks. The acquisition offers strong strategic alignment and access to new growth markets, particularly in women's health. However, much will depend on how effectively Mankind Pharma can integrate BSV and scale its earnings. The company's ability to maintain strong cash flow and manage its increased debt load will be crucial. If management can successfully execute on these fronts, the acquisition could be transformative for Mankind Pharma.

In sum, exciting times lie ahead for shareholders of Mankind Pharma.

Disclaimer: This is not a stock recommendation. Do the due diligence before investing.

Also read: Why is D-Street's love for D-Mart fading?